Zepp Health ADR A

Zepp Health reported revenue of $51.5 million in Q1 2026, up 33.8% year over year, supported by several new wearable products. Gross margin rose to 37.7%, operating loss improved to $6.3 million, and adjusted net loss narrowed slightly to $17.9 million. The stock rose 3.55% in after-hours trading. Management expects EPS of $0.10 for FY2026 and $1.16 for FY2027, and revenue forecasts of $334 million (FY2026) and $392.78 million (FY2027), but sees risks from higher operating costs and supply chain constraints. » More on de.investing.com

Zepp Health's shares have gained almost 1,100% over the past six months after the company reported accelerating sales driven by strong demand for Amazfit wearables and better-than-expected quarterly revenue. Management projected continued top-line growth and Q3 revenue came in at $75.8 million, up 78.5% year over year, while the company is moving toward profitability. Despite the rally, Zepp remains below its 2018 IPO debut and still posts losses, presenting valuation and execution risks for investors. » More on finance.yahoo.com

Zepp Health reported Q3 2025 revenue up 78.5% to $75.8 million and reached operating breakeven. The company announced new products, an expansion of its ecosystem and a strategic inventory build for the holiday season. For Q4 2025 Zepp Health expects revenue of $82–86 million (growth 38–45%) and aims to improve margins. Management and analysts see risks in supply bottlenecks, tariffs and potential chip supply problems; the stock fell 3.65% in after-hours trading to $37.20. » More on de.investing.com